Role of Rho guanine nucleotide exchange factors in non-small cell lung cancer

References

• de Groot PM, Wu CC, Carter BW, et al. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7(3):220–233.
   PubMed Web of Science ®Google Scholar
• Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019;85. DOI:10.5334/aogh.2352
   PubMed Web of Science ®Google Scholar
• Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454.
   PubMed Web of Science ®Google Scholar
• Etienne-Manneville S, Hall A. Rho gtpases in cell biology. Nature. 2002;420(6916):629–635.
   PubMed Web of Science ®Google Scholar
• Haga RB, Ridley AJ. Rho gtpases: Regulation and roles in cancer cell biology. Small GTPases. 2016;7(4):207–221.
   PubMedGoogle Scholar
• Kumawat A, Chakrabarty S, Kulkarni K. Nucleotide dependent switching in rho gtpase: Conformational heterogeneity and competing molecular interactions. Sci Rep. 2017;7(1):1–11.
   PubMedGoogle Scholar
• Zou T, Mao X, Yin J, et al. Emerging roles of RAC1 in treating lung cancer patients. Clin Genet. 2017;91(4):520–528.
   PubMed Web of Science ®Google Scholar
• Konstantinidou G, Ramadori G, Torti F, et al. Rhoa-fak is a required signaling axis for the maintenance of kras-driven lung adenocarcinomas. Cancer Discov. 2013;3(4):444–457.
   PubMed Web of Science ®Google Scholar
• Xiao X-H, Lv L-C, Duan J, et al. Regulating cdc42 and its signaling pathways in cancer: Small molecules and microrna as new treatment candidates. Molecules. 2018;23(4):787.
   PubMed Web of Science ®Google Scholar
• Porter AP, Papaioannou A, Malliri A. Deregulation of rho gtpases in cancer. Small GTPases. 2016;7(3):123–138.
   PubMedGoogle Scholar
• Sosa MS, Lopez-Haber C, Yang C, et al. Identification of the rac-gef p-rex1 as an essential mediator of erbb signaling in breast cancer. Mol Cell. 2010;40(6):877–892.
   PubMed Web of Science ®Google Scholar
• Cardama GA, González N, Maggio J, et al. Rho gtpases as therapeutic targets in cancer. Int J Oncol. 2017;51(4):1025–1034.
   PubMed Web of Science ®Google Scholar
• Lawson CD, Ridley AJ. Rho gtpase signaling complexes in cell migration and invasion. J Cell Biol. 2018;217(2):447–457.
   PubMed Web of Science ®Google Scholar
• Cook DR, Rossman KL, Der CJ. Rho guanine nucleotide exchange factors: Regulators of rho gtpase activity in development and disease. Oncogene. 2014;33(31):4021–4035.
   PubMed Web of Science ®Google Scholar
• Lazer G, Katzav S. Guanine nucleotide exchange factors for rhogtpases: Good therapeutic targets for cancer therapy? Cell Signal. 2011;23(6):969–979.
   PubMed Web of Science ®Google Scholar
• Kumar S, Stecher G, Tamura K. Mega7: Molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33(7):1870–1874.
   PubMed Web of Science ®Google Scholar
• He Z, Zhang H, Gao S, et al. Evolview v2: An online visualization and management tool for customized and annotated phylogenetic trees. Nucleic Acids Res. 2016;44(W1):W236–W241.
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. String v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–d613.
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (New York, NY). 2007;9(2):166.
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, et al. Oncomine: a cancer microarray database and integrated data-mining platform. Neoplasia (New York, NY). 2004;6(1):1.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. Gepia: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. Ualcan: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658.
   PubMed Web of Science ®Google Scholar
• Győrffy B, Surowiak P, Budczies J, et al. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013;8(12):e82241–e82241.
   PubMed Web of Science ®Google Scholar
• Li Q, Birkbak NJ, Gyorffy B, et al. Jetset: Selecting the optimal microarray probe set to represent a gene. BMC Bioinformatics. 2011;12(1): 474–474.
   Google Scholar
• Győrffy B, Benke Z, Lánczky A, et al. Recurrenceonline: An online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res Treat. 2012;132(3):1025–1034.
   PubMed Web of Science ®Google Scholar
• Koch A, De Meyer T, Jeschke J, et al. Mexpress: Visualizing expression, DNA methylation and clinical tcga data. BMC Genomics. 2015;16(1):636.
   PubMed Web of Science ®Google Scholar
• Koch A, Jeschke J, Van Criekinge W, et al. Mexpress update 2019. Nucleic Acids Res. 2019;47(W1):W561–W565.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cbioportal. Sci Signal. 2013;6(269): pl1–pl1.
   Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Nat Acad Sci. 2005;102(43):15545–15550.
   PubMed Web of Science ®Google Scholar
• Liberzon A, Subramanian A, Pinchback R, et al. Molecular signatures database (msigdb) 3.0. Bioinformatics. 2011;27(12):1739–1740.
   PubMed Web of Science ®Google Scholar
• Faruki H, Mayhew GM, Serody JS, et al. Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape. J Thorac Oncol. 2017;12(6):943–953.
   PubMed Web of Science ®Google Scholar
• Brägelmann J, Böhm S, Guthrie MR, et al. Family matters: How myc family oncogenes impact small cell lung cancer. Cell Cycle. 2017;16(16):1489–1498.
   PubMed Web of Science ®Google Scholar
• Soucek L, Whitfield JR, Sodir NM, et al. Inhibition of myc family proteins eradicates kras-driven lung cancer in mice. Genes Dev. 2013;27(5):504–513.
   PubMed Web of Science ®Google Scholar
• Yang S, Liu Y, Li M-Y, et al. Foxp3 promotes tumor growth and metastasis by activating wnt/β-catenin signaling pathway and emt in non-small cell lung cancer. Mol Cancer. 2017;16(1): 124–124. DOI:10.1186/s12943-017-0700-1
   Google Scholar
• Tan EC, Leung T, Manser E, et al. The human active breakpoint cluster region-related gene encodes a brain protein with homology to guanine nucleotide exchange proteins and gtpase-activating proteins. J Biol Chem. 1993;268(36):27291–27298.
   PubMed Web of Science ®Google Scholar
• Cunnick JM, Schmidhuber S, Chen G, et al. Bcr and abr cooperate in negatively regulating acute inflammatory responses. Mol Cell Biol. 2009;29(21):5742–5750.
   PubMed Web of Science ®Google Scholar
• Namasu CY, Katzerke C, Bräuer-Hartmann D, et al. Abr, a novel inducer of transcription factor c/ebpα, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia. Oncotarget. 2017;8(61):103626.
   PubMedGoogle Scholar
• Welch HC, Coadwell WJ, Ellson CD, et al. P-rex1, a ptdins (3, 4, 5) p3-and gβγ-regulated guanine-nucleotide exchange factor for rac. Cell. 2002;108(6):809–821.
   PubMed Web of Science ®Google Scholar
• Welch HCE, Condliffe AM, Milne LJ, et al. P-rex1 regulates neutrophil function. Curr Biol. 2005;15(20):1867–1873.
   PubMed Web of Science ®Google Scholar
• Cervantes-Villagrana RD, Adame-García SR, García-Jiménez I, et al. Gβγ signaling to the chemotactic effector p-rex1 and mammalian cell migration is directly regulated by gαq and gα13 proteins. J Biol Chem. 2019;294(2):531–546.
   PubMed Web of Science ®Google Scholar
• Lindsay CR, Lawn S, Campbell AD, et al. P-rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat Commun. 2011;2(1):1–9.
   Google Scholar
• Qin J, Xie Y, Wang B, et al. Upregulation of pip3-dependent rac exchanger 1 (p-rex1) promotes prostate cancer metastasis. Oncogene. 2009;28(16):1853–1863.
   PubMed Web of Science ®Google Scholar
• Dillon LM, Bean JR, Yang W, et al. P-rex1 creates a positive feedback loop to activate growth factor receptor, pi3k/akt and mek/erk signaling in breast cancer. Oncogene. 2015;34(30):3968–3976.
   PubMed Web of Science ®Google Scholar
• Nishihara H, Kobayashi S, Hashimoto Y, et al. Non-adherent cell-specific expression of dock2, a member of the human cdm-family proteins. Biochimica Et Biophysica Acta (BBA) - Molecular Cell Research. 1999;1452(2):179–187.
   PubMed Web of Science ®Google Scholar
• Gadea G, Blangy A. Dock-family exchange factors in cell migration and disease. Eur J Cell Biol. 2014;93(10–12):466–477.
   PubMed Web of Science ®Google Scholar
• Miao S, Zhang RY, Wang W, et al. Overexpression of dedicator of cytokinesis 2 correlates with good prognosis in colorectal cancer associated with more prominent CD8+ lymphocytes infiltration: a colorectal cancer analysis. J Cell Biochem. 2018;119(11):8962–8970.
   PubMed Web of Science ®Google Scholar
• Wang L, Nishihara H, Kimura T, et al. Dock2 regulates cell proliferation through rac and erk activation in b cell lymphoma. Biochem Biophys Res Commun. 2010;395(1):111–115.
   PubMed Web of Science ®Google Scholar
• Yajnik V, Paulding C, Sordella R, et al. Dock4, a gtpase activator, is disrupted during tumorigenesis. Cell. 2003;112(5):673–684.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Harada K, Negishi M, et al. Dock4 forms a complex with sh3yl1 and regulates cancer cell migration. Cell Signal. 2014;26(5):1082–1088.
   PubMed Web of Science ®Google Scholar
• Westbrook JA, Wood SL, Cairns DA, et al. Identification and validation of dock4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. J Pathol. 2019;247(3):381–391.
   PubMed Web of Science ®Google Scholar
• Pfeifer GP. Defining driver DNA methylation changes in human cancer. Int J Mol Sci. 2018;19(4):1166.
   PubMed Web of Science ®Google Scholar
• Li L, Li C, Mao H, et al. Epigenetic inactivation of the cpg demethylase tet1 as a DNA methylation feedback loop in human cancers. Sci Rep. 2016;6(1): 26591–26591. DOI:10.1038/srep26591
   Google Scholar
• Jin B, Li Y, Robertson KD. DNA methylation: superior or subordinate in the epigenetic hierarchy? Genes Cancer. 2011;2(6):607–617.
   PubMedGoogle Scholar
• Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of cpg dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci U S A. 2006;103(5):1412–1417.
   PubMed Web of Science ®Google Scholar
• Belinsky SA. Silencing of genes by promoter hypermethylation: Key event in rodent and human lung cancer. Carcinogenesis. 2005;26(9):1481–1487.
   PubMed Web of Science ®Google Scholar
• Langevin SM, Kratzke RA, Kelsey KT. Epigenetics of lung cancer. Transl Res. 2015;165(1):74–90.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Miteva MA, Wang L, et al. Analyzing effects of naturally occurring missense mutations. Comput Math Methods Med. 2012;2012: 805827–805827.
   Web of Science ®Google Scholar
• Kim KH, Roberts CWM. Targeting ezh2 in cancer. Nat Med. 2016;22(2):128–134.
   PubMed Web of Science ®Google Scholar
• Stine ZE, Walton ZE, Altman BJ, et al. Myc, metabolism, and cancer. Cancer Discov. 2015;5(10):1024–1039.
   PubMed Web of Science ®Google Scholar
• Chen H, Liu H, Qing G. Targeting oncogenic myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018;3(1): 5–5.
   Google Scholar
• Gabay M, Li Y, Felsher DW. Myc activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med. 2014;4(6):a014241.
   PubMed Web of Science ®Google Scholar
• Lorenz J, Friedberg T, Paulus R, et al. Oncogene overexpression in non-small-cell lung cancer tissue prevalence and clinicopathological significance. Clin Investig. 1994;72(2):156–163.
   PubMedGoogle Scholar
• Mustachio LM, Roszik J, Farria AT, et al. Repression of gcn5 expression or activity attenuates c-myc expression in non-small cell lung cancer. Am J Cancer Res. 2019;9(8):1830–1845.
   PubMed Web of Science ®Google Scholar
• Lemjabbar-Alaoui H, Hassan OU, Yang YW, et al. Lung cancer: Biology and treatment options. Biochim Biophys Acta. 2015;1856(2):189–210.
   PubMed Web of Science ®Google Scholar
• Woods D, Turchi JJ. Chemotherapy induced DNA damage response: convergence of drugs and pathways. Cancer Biol Ther. 2013;14(5):379–389.
   PubMed Web of Science ®Google Scholar
• Sen T, Gay CM, Byers LA. Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. Transl Lung Cancer Res. 2018;7(1):50–68.
   PubMed Web of Science ®Google Scholar
• Butkiewicz D, Drosik A, Suwiński R, et al. Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinum-based chemotherapy. Int J Cancer. 2012;131(7):E1100–E1108.
   PubMed Web of Science ®Google Scholar
• Vaughan EM, Miller AL, Yu H-YE, et al. Control of local rho gtpase crosstalk by abr. Curr Biol. 2011;21:270–277.
   PubMed Web of Science ®Google Scholar
• Yu P, Fu Y-X. Tumor-infiltrating t lymphocytes: friends or foes? Lab Invest. 2006;86(3):231–245.
   PubMed Web of Science ®Google Scholar
• Geng Y, Shao Y, He W, et al. Prognostic role of tumor-infiltrating lymphocytes in lung cancer: a meta-analysis. Cell Physiol Biochem. 2015;37(4):1560–1571.
   PubMed Web of Science ®Google Scholar